JAMA
Original Investigation
April 22, 2024
Joshua D.ÌýWallach,ÌýPhD, MS; SamuelÌýYoon,ÌýBS, BA; HarryÌýDoernberg,ÌýMM; Laura R.ÌýGlick,ÌýMD; OrianaÌýCiani,ÌýPhD; Rod S.ÌýTaylor,ÌýPhD; MaryamÌýMooghali,ÌýMD; ReshmaÌýRamachandran,ÌýMD, MHS, MPP; Joseph S.ÌýRoss,ÌýMD, MHS
online first
JAMA. 2024; 10.1001/jama.2024.4175
This study examines the strength of association between surrogate markers used as primary end points in clinical trials to support FDA approval of drugs treating nononcologic chronic diseases and clinical outcomes.